Acadia Pharmaceuticals (ACAD) FY2016 results: revenue $17 million, up 28311.5% on the year
Acadia Pharmaceuticals Inc. (ACAD) reported revenue of $17 million for fiscal 2016, the year ended 31 December 2016, up 28311.5% on the year before. Net income was -$271 million, and diluted earnings per share $-2.34. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2017.
Revenue
$17 million
+28,311.5% on the year
FY2009FY2016
Operating margin
-1574.1%
-269855.7% a year earlier
FY2009FY2016
Net income
-$271 million
FY2009FY2016
Diluted EPS
-$2.34
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
17.3
0.1
0.1
+28,311.5%
Cost of revenue
3.1
n/a
n/a
Gross profit
14.3
n/a
n/a
Gross margin
82.2%
n/a
n/a
Research and development
99.3
73.9
60.6
+34.4%
Selling, general and administrative
186
88.3
32.7
+111.2%
Operating income
-273
-165
-93.2
Operating margin
-1574.1%
-269855.7%
-77691.7%
Pre-tax income
-270
-164
-92.5
Income tax
1.3
0.3
0.0
+306.4%
Net income
-271
-164
-92.5
Net margin
-1565.9%
-269578.7%
-77062.5%
Diluted EPS
-$2.34
-$1.63
-$0.95
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
-208
-122
-66.4
Capital expenditure
1.5
2.1
0.2
-29.7%
Free cash flow
-210
-124
-66.6
Free cash flow margin
-1211.2%
-203173.8%
-55511.7%
Cash from investing
-262
n/a
n/a
Cash from financing
534
n/a
n/a
Depreciation and amortisation
1.8
0.6
0.2
+182.5%
Share-based compensation
55.3
40.2
16.0
+37.5%
Shares outstanding at period end
121m
102m
100m
+19.1%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
518
200
309
+159.5%
Other liabilities
42.7
22.1
16.0
+93.1%
Total liabilities and equity
561
222
325
+152.9%
Fixed assets
3.1
2.2
0.6
+39.9%
Intangible assets
7.0
n/a
n/a
Investments
365
113
261
+223.4%
Cash and equivalents
164
102
61.9
+60.2%
Receivables
5.9
n/a
n/a
Inventory
4.2
n/a
n/a
Other assets
11.9
4.6
2.4
+161.9%
Total assets
561
222
325
+152.9%
10-K for the year ended 31 December 2016, filed 28 February 2017: the filing.